increas
autoantibodi
reactiv
plasma
myelodysplast
syndrom
md
patient
may
provid
novel
diseas
signatur
possibl
earli
detect
twostag
studi
investig
immunoglobulin
g
reactiv
plasma
md
acut
myeloid
leukemia
post
md
patient
healthi
cohort
exploratori
stage
util
highthroughput
protein
array
identifi
highinterest
protein
show
increas
reactiv
patient
subgroup
compar
healthi
control
valid
stage
ii
design
new
array
focus
protein
identifi
stage
expand
initi
cohort
valid
increas
antibodi
reactiv
patient
enabl
sampl
classif
stabl
md
healthi
individu
also
detect
elev
protein
level
md
patient
plasma
discoveri
increas
specif
autoantibodi
reactiv
md
patient
provid
molecular
signatur
classif
supplement
exist
risk
categor
may
enhanc
diagnost
prognost
capabl
md
yelodysplast
syndrom
md
encompass
divers
rang
hematolog
disord
variabl
clinic
outcom
result
individu
patient
clinic
biolog
featur
md
pathogenesi
involv
multifacet
factor
relat
intrins
hematopoiet
precursor
cell
abnorm
preval
share
pathogenesi
caus
ineffect
hematopoiesi
md
involv
vari
degre
apoptosi
hematopoiet
cell
linag
recent
genom
approach
concentr
effect
specif
gene
mutat
associ
signal
pathway
role
md
develop
outcom
includ
tendenc
transit
aggress
diseas
stage
current
prognosi
patient
outcom
greatli
facilit
establish
intern
prognost
score
system
ipss
recent
revis
ipssr
ipss
take
account
multipl
clinic
marker
classifi
lower
risk
patient
low
intermedi
improv
prognos
compar
higher
risk
featur
intermedi
high
autoantibodi
reactiv
profil
human
plasma
employ
multipl
disord
includ
immun
respons
sever
acut
respiratori
syndrom
diabet
well
cancer
use
protein
microarray
md
patient
immunolog
abnorm
observ
furthermor
higher
rate
immun
relat
cell
abnorm
report
md
predominantli
earlierstag
compar
laterstag
md
patient
includ
alter
immun
cell
subpopul
name
regulatori
inhibitori
cell
addit
diseas
progress
found
concord
dynam
shorten
telomer
observ
md
precursor
short
telomer
dna
damag
hematopoiet
precursor
includ
md
patient
associ
cellular
protein
secret
assess
diseas
relat
abnorm
autoantibodi
reactiv
possibl
immun
relat
respons
md
patient
variou
stage
util
high
throughput
protein
array
allow
simultan
monitor
chang
autoantibodi
reactiv
thousand
human
protein
reactiv
antibodi
profil
protein
microarray
principl
enzymelink
immunosorb
assay
elisa
antigenprimari
antibodysecondari
antibodi
format
addit
advantag
includ
higher
throughput
use
fluoresc
signal
secondari
antibodi
instead
less
reproduc
enzymelink
chromogen
signal
protein
microarray
report
higher
throughput
sensit
wider
detect
rang
compar
tradit
elisa
method
variou
applic
main
hypothesi
md
elicit
specif
autoantibodi
respons
henc
search
autoantigen
biomark
relat
variou
md
patient
subgroup
compar
control
plasma
use
protein
microarray
technolog
protoarray
v
invitrogen
focus
retrospect
classif
subject
stabl
md
patient
smd
transform
acut
myeloid
leukemia
aml
least
month
gener
multipl
year
transform
md
tmd
patient
eventu
acquir
aml
within
period
aml
post
md
l
patient
alreadi
transform
aml
previous
classifi
md
patient
md
aml
patient
compar
healthi
cohort
individu
studi
conduct
two
sequenti
separ
stage
exploratori
stage
multipl
patient
sampl
protein
test
immunoglobulin
g
igg
reactiv
ii
valid
stage
use
smaller
highinterest
subset
protein
identifi
stage
base
retrospect
classif
expand
larger
cohort
use
focus
subset
allow
us
util
protein
display
greatest
degre
differenti
igg
reactiv
patient
group
healthi
control
differ
experiment
design
illustr
fig
describ
detail
result
stage
multipl
plasma
sampl
obtain
male
patient
median
age
rang
healthi
cohort
median
age
rang
discuss
method
sampl
use
studi
obtain
earli
patient
cours
enabl
assess
predict
potenti
prolong
clinic
cours
md
patient
ie
smd
time
sampl
collect
patient
classifi
use
prospect
clinic
riskbas
ipss
system
follow
longterm
monitor
patient
sampl
also
assign
retrospect
classif
smd
tmd
l
state
previous
defin
patient
compar
healthi
cohort
tabl
identifi
highprior
set
marker
fig
stage
describ
valid
stage
ii
fig
initi
subject
pool
enlarg
includ
male
femal
individu
patient
smd
tmd
l
healthi
control
tabl
note
differ
median
age
patient
healthi
group
taken
consider
analysi
varianc
anova
model
ensur
statist
factor
final
result
stage
sampl
obtain
male
patient
prior
studi
patient
ovarian
prostat
carcinoma
show
gender
differ
antibodi
reactiv
stage
ii
assess
sampl
investig
carri
two
stage
stage
protoarray
use
identifi
high
prioriti
set
candid
biomark
success
spot
onto
custom
array
stage
ii
focus
valid
part
investig
stage
ii
identifi
biomark
candid
also
detect
use
elisa
assay
candid
biomark
stage
show
distinct
higher
reactiv
md
patient
compar
healthi
cohort
b
higher
standard
intens
indic
yellow
low
blueturquois
valid
protein
stage
ii
mark
red
c
binari
statist
comparison
patient
subgroup
healthi
cohort
result
differ
set
autoantibodi
specif
respect
classif
venn
diagram
indic
overlap
comparison
candid
biomark
specif
smd
patient
subgroup
variou
associ
includ
cancer
discov
use
ingenu
pathway
network
analysi
ingenuityh
system
http
wwwingenuitycom
wwwnaturecomscientificreport
scientif
report
doi
gender
found
differ
result
md
patient
stage
result
initi
screen
protein
array
contain
protein
identifi
autoantigen
high
interest
show
aberrantli
high
reactiv
patient
subgroup
compar
healthi
cohort
fig
venn
diagram
fig
indic
minim
overlap
differ
retrospect
md
classif
smd
group
show
greatest
differ
compar
healthi
group
note
greater
number
avail
sampl
furthermor
consid
whole
result
support
hypothesi
md
patient
display
distinct
autoantibodi
respons
compar
healthi
cohort
see
also
supplementari
tabl
initi
screen
identifi
relev
molecular
associ
ingenuityh
ipa
knowledg
databas
http
wwwingenuitycom
stage
ii
result
highinterest
protein
stage
see
method
detail
test
valid
use
custom
protein
array
protein
success
produc
spot
fig
take
account
multipl
sourc
variabl
employ
anova
model
filter
result
elimin
effect
due
print
replic
batch
effect
subject
age
see
method
fig
identifi
protein
fig
show
aberrantli
increas
reactiv
patient
compar
healthi
p
bonferroni
correct
factor
consid
signific
confound
effect
correspond
binari
group
comparison
mean
differ
also
statist
signific
mannwhitney
utest
mean
intens
p
smd
tmd
l
versu
healthi
respect
mean
intens
p
smd
l
versu
healthi
respect
mean
intens
p
smd
tmd
l
versu
healthi
respect
classifi
differ
sampl
patient
subgroup
implement
kernel
discrimin
analysi
kda
use
transform
intens
success
classif
retrospect
class
particularli
smd
fig
consid
smd
healthi
cohort
smd
sampl
classifi
correctli
time
standard
deviat
sd
healthi
sampl
sd
expand
classif
md
l
patient
significantli
affect
classif
smd
healthi
cohort
fig
howev
classif
lower
known
tmd
sd
l
sd
sampl
autoantibodi
reactivitybas
classif
work
less
well
classifi
sampl
known
ipss
class
fig
best
classif
intermedi
sd
classif
healthi
sampl
sd
detect
three
protein
interest
plasma
use
enzymelink
immunosorb
assay
elisa
differenti
protein
level
found
statist
signific
anova
analysi
bonferroni
correct
p
respect
fig
differenti
protein
trend
retrospect
class
reflect
autoantibodi
reactiv
post
hoc
test
bonferroni
p
display
differ
patient
group
versu
healthi
well
l
versu
tmd
differenti
protein
level
show
opposit
trend
compar
correspond
autoantibodi
reactiv
fig
c
post
hoc
test
bonferroni
p
display
differ
healthi
versu
tmd
smd
well
l
tmd
smd
investig
demonstr
differenti
autoantibodi
reactiv
md
patient
subset
distinct
healthi
individu
autoantibodi
display
increas
protein
reactiv
compar
healthi
patient
includ
sever
uniqu
protein
tmd
smd
l
initi
valid
stage
stage
ii
investig
find
increas
antibodi
reactiv
protein
predominantli
occur
smd
patient
consist
prior
data
indic
earli
stage
md
higher
degre
immunerel
abnorm
later
stage
patient
protein
involv
cancerrelev
biolog
process
apoptosi
associ
involv
autoimmun
respons
differenti
reactiv
antibodi
earli
stage
md
healthi
individu
also
diagnost
util
sinc
clinic
distinct
morpholog
often
difficult
three
protein
valid
stage
ii
investig
present
robust
set
show
increas
autoantibodi
reactiv
md
patient
detect
autoantibodi
reactiv
protein
offer
possibl
new
connect
immun
respons
tumor
format
detect
particularli
note
vakt
murin
thymoma
viral
oncogen
homolog
protein
kinas
b
gamma
known
activ
involv
multipl
cancer
includ
breast
cancer
tumorigenesi
melanoma
lung
cancer
ovarian
cancer
cell
cycl
involv
previou
studi
gene
overexpress
deregul
akt
pathway
detect
gene
express
profil
addit
observ
differenti
autoantibodi
reactiv
correspond
protein
level
make
compel
case
involv
md
highlight
potenti
biomark
condit
smd
igg
receptor
involv
multipl
antibodi
process
fcreceptor
target
multipl
therapeut
approach
cancer
inflammatori
state
includ
genotyp
associ
rituximab
respons
protein
level
determin
elisa
show
opposit
trend
compar
correspond
autoantibodi
reactiv
protein
level
may
reflect
possibl
observ
autoantibodi
reactiv
due
nonspecif
fcreceptor
interact
rather
increas
amount
specif
antibodi
necessarili
impli
correl
amount
antigen
strength
reactiv
fact
mani
highli
express
protein
autogen
eg
albumin
neg
acutephas
protein
decreas
plasma
level
immun
respons
small
amount
allergen
could
trigger
sever
immun
respons
adpribosyl
factorlik
involv
lysosom
traffick
posit
influenc
mtor
express
mammalian
target
rapamycin
autophagosom
format
may
also
associ
metastasi
tumorigenesi
patient
classif
may
made
two
separ
classif
scheme
prospect
ipss
retrospect
stl
healthi
consid
classif
scheme
show
good
overlap
ipss
low
intermedi
risk
categori
account
respect
smd
patient
total
use
autoantibodi
reactiv
classifi
patient
two
classif
scheme
retrospect
ipss
show
better
concord
autoantibodi
reactiv
stabl
patient
retrospect
classif
rather
ipss
slightli
lower
healthi
patient
classif
ipss
better
healthi
patient
suggest
combin
ipss
classif
scheme
autoantibodi
reactiv
may
improv
clinic
diagnosi
smd
patient
maintain
low
number
fals
posit
healthi
individu
furthermor
autoantibodi
reactivitybas
classif
reli
direct
molecular
marker
signatur
may
possibl
applic
altern
supplement
ipss
risk
estim
especi
earli
detect
smd
patient
final
detect
autoantibodi
reactiv
would
requir
plasma
minim
invas
patient
studi
discov
differenti
autoantibodi
reactiv
md
identifi
autoantibodi
particular
prognost
md
subset
demonstr
protein
microarray
provid
power
approach
identifi
uniqu
biomark
associ
diseas
investig
chose
sensit
focus
protein
array
approach
tradit
chromogen
elisa
valid
purpos
envis
highthroughput
fluorescencebas
method
protein
microarray
may
eventu
replac
tradit
chromogen
elisa
clinic
test
expect
elisa
clinic
test
may
also
develop
futur
base
find
regard
possibl
specif
find
although
autoantibodi
studi
yet
report
hematolog
malign
combin
autoantibodi
reactiv
observ
md
patient
distinct
report
patient
ovarian
prostat
cancer
diabet
respiratori
infect
expect
find
increas
autoantibodi
reactiv
md
patient
rel
prolong
clinic
cours
encourag
futur
studi
larger
patient
cohort
help
substanti
prognost
import
data
explor
underli
molecular
mechan
identifi
autoantibodi
reactiv
may
greatli
enhanc
diagnost
prognost
capabl
md
plasma
autoantibodi
reactiv
profil
protein
array
stage
autoantibodi
reactiv
profil
retrospect
patient
subset
tabl
use
invitrogen
protoarray
protein
microarray
uniqu
human
protein
spot
duplic
signal
total
includ
control
describ
previous
parallel
duplic
neg
control
array
probe
plasma
sampl
dilut
ml
wash
buffer
pb
tween
rotiblock
protoarray
dri
scan
use
genepix
microarray
scanner
molecular
devic
sunnyval
ca
obtain
array
imag
analyz
genepix
pro
molecular
devic
obtain
featur
locat
signal
foreground
background
intens
quantif
correspond
identif
inform
gpr
file
format
addit
probe
igg
reactiv
nm
channel
array
spot
protein
contain
glutathion
stransferas
gst
fusion
tag
second
channel
nm
screen
allow
us
probe
gst
intens
use
proxi
protein
concentr
per
array
spot
see
also
supplementari
fig
stage
ii
custom
protein
array
creat
probe
autoantibodi
reactiv
enlarg
cohort
tabl
figur
array
produc
invitrogen
use
protoarray
technolog
figur
compris
block
duplic
protein
spot
total
per
block
protein
stage
use
analyz
protein
reactiv
one
subject
sampl
per
block
includ
differenti
react
protein
interest
identifi
stage
randomli
select
control
protein
probe
procedur
carri
stage
describ
includ
neg
control
array
imag
analyz
stage
obtain
signal
inform
block
consid
separ
includ
probe
gst
intens
array
analys
stage
array
analyz
multistep
process
involv
interand
intraarray
normal
signal
comparison
group
identifi
initi
highinterest
protein
set
display
increas
igg
reactiv
patient
subgroup
fig
array
per
channel
intraarray
normal
perform
via
implement
procat
algorithm
slide
window
paramet
length
take
account
local
background
subtract
local
intens
normal
across
array
local
intens
adjust
necessari
correct
array
variat
stem
print
probe
procedur
adjust
probe
scan
procedur
variat
interarray
intens
quantil
normal
probe
intens
compar
tabl
actual
data
point
superimpos
densiti
comput
kda
md
subgroup
show
overlap
c
equival
classif
ipss
risk
group
perform
well
classif
retrospect
subset
shown
classif
ac
perform
kda
use
standard
autoantibodi
reactiv
repres
three
coordin
assign
sampl
point
threedimension
space
classif
involv
crossvalid
repetit
data
partit
assess
varianc
median
classif
see
also
supplementari
tabl
nb
classif
matric
display
classif
median
might
lead
lower
sum
due
round
mismatch
total
sum
sampl
use
row
binari
comparison
patient
retrospect
healthi
group
procedur
previous
shown
highli
reproduc
r
technic
replic
duplic
spot
studi
compar
differ
patient
subgroup
one
anoth
specif
interest
signal
show
increas
reactiv
retrospect
analyz
md
patient
versu
healthi
control
group
particularli
smd
assess
statist
signific
twotail
mannwhitney
test
mathematica
multipl
hypothes
bonferroni
adjust
p
filter
control
signal
protein
spot
inconsist
print
array
ie
display
differenti
gsttag
signal
due
variabl
array
print
total
protein
show
increas
reactiv
cutoff
p
bonferroni
adjust
p
identifi
highinterest
protein
comparison
md
subset
healthi
cohort
fig
use
pathway
function
analysi
ipa
ingenuityh
system
http
wwwingenuitycom
identifi
relev
biolog
function
ingenu
knowledg
base
fig
determin
probabl
biolog
function
assign
data
set
due
chanc
alon
p
valu
calcul
use
righttail
fisher
exact
test
p
addit
canon
pathway
ipa
librari
statist
signific
ascertain
base
pvalu
p
fisher
exact
test
ratio
molecul
data
set
compar
total
network
see
also
supplementari
inform
array
analys
stage
ii
subsequ
valid
stage
studi
success
express
protein
onto
custom
focus
array
describ
note
protein
initi
list
candid
includ
valid
could
either
success
express
isol
print
lack
proper
clone
low
viabil
specif
clone
low
yield
isol
print
error
etc
pass
strict
secondari
qualiti
control
select
focus
array
print
ad
measur
valid
reproduc
larg
gstsignal
variat
neg
flag
rais
scan
satur
signal
nonreproduc
varianc
stabil
signal
analysi
addit
studi
expand
much
larger
cohort
tabl
protein
array
scan
describ
block
correspond
differ
patient
patient
sampl
perform
duplic
use
interand
intraarray
normal
stage
fig
appli
per
block
signal
protein
spot
transform
normal
distribut
use
boxcox
transform
protein
analyz
use
anova
model
check
varianc
subject
subgroup
retrospect
classif
replic
duplic
sampl
duplic
protein
spot
subject
age
gender
marrow
blast
level
healthi
ipss
blast
categori
leukem
statu
random
effect
batch
effect
stage
ii
investig
fig
possibl
interact
also
consid
signal
show
signific
primari
effect
signific
interact
use
bonferroni
posthoc
test
correct
multipl
group
featur
comparison
select
highconfid
signal
interest
addit
anova
use
screen
signal
show
signific
effect
due
replic
subject
age
random
furthermor
ensur
protein
level
vari
array
statist
signific
differenti
gst
signal
elimin
base
anova
standard
transform
reactiv
level
found
higher
patient
versu
healthi
cohort
fig
protein
use
classif
name
kda
r
packag
ks
use
unconstrain
smooth
crossvalid
method
bandwidth
select
linear
discrimin
analysi
lda
r
packag
mass
see
supplementari
tabl
kda
outperform
lda
retrospect
ipss
classif
method
involv
assign
class
crossvalid
perform
random
data
partit
fig
elisa
util
elisa
kit
measur
plasma
level
dilut
pathscanh
catalog
cell
signal
dilut
catalog
uscn
life
scienc
inc
dilut
mybiosourc
catalog
use
sampl
subject
total
smd
tmd
l
healthi
subject
test
triplic
follow
manufactur
instruct
fig
